Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics Analyst Ratings
Buy Rating Affirmed for Tempest Therapeutics Amid Positive Developments and Strategic Roche Collaboration
Scotiabank Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $13
Scotiabank Keeps Their Buy Rating on Tempest Therapeutics (TPST)
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics Analyst Ratings
Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Phase 3 Outlook and Funding Uncertainties
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Buy Rating Affirmed for Tempest Therapeutics Amid Strong Clinical Results and Solid Financials
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), CVS Health (CVS) and Tempest Therapeutics (TPST)
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
HC Wainwright & Co. : The Tempest Therapeutics (TPST.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $47.00.
Tempest Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
HC Wainwright & Co. : The Tempest Therapeutics (TPST.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $47.00.
Tempest Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target